High-throughput sequencing in acute lymphoblastic leukemia: Follow-up of minimal residual disease and emergence of new clones

Abstract : Minimal residual disease (MRD) is known to be an independent prognostic factor in patients with acute lymphoblastic leukemia (ALL). High-throughput sequencing (HTS) is currently used in routine practice for the diagnosis and follow-up of patients with hematological neoplasms. In this retrospective study, we examined the role of immunoglobulin/T-cell receptor-based MRD in patients with ALL by HTS analysis of immunoglobulin H and/or T-cell receptor gamma chain loci in bone marrow samples from 11 patients with ALL, at diagnosis and during follow-up. We assessed the clinical feasibility of using combined HTS and bioinformatics analysis with interactive visualization using Vidjil software. We discuss the advantages and drawbacks of HTS for monitoring MRD. HTS gives a more complete insight of the leukemic population than conventional real-time quantitative PCR (qPCR), and allows identification of new emerging clones at each time point of the monitoring. Thus, HTS monitoring of Ig/TCR based MRD is expected to improve the management of patients with ALL.
Liste complète des métadonnées

Littérature citée [32 références]  Voir  Masquer  Télécharger

https://hal.archives-ouvertes.fr/hal-01404817
Contributeur : Mathieu Giraud <>
Soumis le : samedi 3 février 2018 - 13:44:57
Dernière modification le : mardi 3 juillet 2018 - 11:22:24
Document(s) archivé(s) le : jeudi 3 mai 2018 - 10:12:58

Fichier

2017-SalsonGiraudCaillaultGrar...
Fichiers produits par l'(les) auteur(s)

Identifiants

Citation

Mikael Salson, Mathieu Giraud, Aurélie Caillault, Nathalie Grardel, Nicolas Duployez, et al.. High-throughput sequencing in acute lymphoblastic leukemia: Follow-up of minimal residual disease and emergence of new clones. Leukemia Research, Elsevier, 2017, 53, pp.1-7. 〈10.1016/j.leukres.2016.11.009〉. 〈hal-01404817〉

Partager

Métriques

Consultations de la notice

328

Téléchargements de fichiers

86